Cyclin-dependent kinase 20 (CDK20)

Cyclin-dependent kinase 20 (CDK20), also known as cell cycle-related kinase (CCRK), is a serine/threonine protein kinase of the cyclin-dependent kinase family that regulates cell cycle progression, predominantly the G1-to-S phase transition. CDK20 primarily activates CDK2 by phosphorylating it on threonine 160, thereby promoting cell proliferation. It interacts with cyclin H and is structurally similar to CDK7, although its CDK-activating kinase activity is debated and may depend on complex formation. CDK20 is involved in cilium/flagellum assembly and hedgehog pathway signal transduction, influencing GLI2 activation and ciliary architecture. Its expression is upregulated in diverse cancers, where it facilitates unchecked cell proliferation and may contribute to carcinogenesis via multiple signaling mechanisms (Wnt, EZH2/NF-κB, KEAP1-NRF2). Alternative splicing generates multiple isoforms, including a cardiac-specific form involved in heart failure pathophysiology. CDK20 represents a novel and emerging therapeutic target, but as of 2024, no clinically established small-molecule inhibitors are approved or in late-stage development.

Other names

CCRK (cell cycle-related kinase)PNQALRECDCHCAK-kinase p42p42CDK-activating kinase p42Cell division protein kinase 20Cyclin-dependent protein kinase HCyclin-kinase-activating kinase p42

Inhibition of kinase activity (expected mechanism for any putative drug: blocks CDK20's enzyme function, cell cycle progression, and mitogenic signaling pathways). Interference with complex formation with cyclin H or interaction with regulatory protein partners (as described in pathway context).